Key Highlights
- Sonoma Biotherapeutics receives $45 million milestone payment from Regeneron.
- Collaboration focuses on engineered Treg therapies for autoimmune diseases.
- Sonoma Bio retains co-promotion rights in the U.S. for future products.
- Regeneron has the option to lead late-stage global commercialization.
Source: Business Wire
Notable Quote
- “This payment marks a significant milestone in our evolution as a company and our collaboration with Regeneron, which has been going extremely well.” — Jeff Bluestone, Ph.D., Chief Executive Officer at Sonoma Biotherapeutics
SoHC's Take
This $45 million milestone payment highlights the ongoing success of Sonoma Biotherapeutics’ collaboration with Regeneron, a partnership combining cutting-edge antibody and T cell receptor technologies with Sonoma Bio’s expertise in regulatory T cell therapies. As both companies work toward co-developing treatments for autoimmune diseases, this collaboration strengthens their shared vision to address unmet medical needs, particularly in areas like inflammatory bowel disease. The mutual financial commitment and shared rights to late-stage product development also demonstrate confidence in the transformative potential of these Treg therapies. Sonoma’s retention of lead candidate SBT-77-7101 signals the company’s strategic focus on expanding its platform while maintaining control over its lead assets.
